Abstract: Three patients with livedoid vasculopathy who received upadacitinib treatment were reported herein, all of whom achieved good curative effects. Patient 1 was a 46-year-old female who was given 15 mg of upadacitinib sustained-release tablets once daily; significant improvement of skin rashes and obvious relief of pain were observed after 4 weeks. Patient 2 was a 15-year-old female who was administered 15 mg of upadacitinib sustained-release tablets once daily; the skin lesions improved significantly after 8 weeks, and the dosage was adjusted to 15 mg every other day for continuous oral administration for 16 weeks, with no recurrence found during follow-up half a year after drug withdrawal. Patient 3 was a 15-year-old male who received 15 mg of upadacitinib sustained-release tablets once daily; ecchymoses subsided after 4 weeks, and during 32 weeks of follow-up, the skin rashes were well-controlled without recurrence. No adverse reactions were observed in the three patients during the treatment period.

Key words: upadacitinib, livedoid vasculopathy, treatment, JAK inhibitor